Meeting Report

Medicare drug price negotiations: impact on healthcare development and patient access to medicines

Published in: Volume 12 / Year 2023 / Issue 3
Page: 95-105

Author byline as per print journal: Michael S Reilly, Esq; Thomas R Barker, Esq, JD; Charles M Clapton, Esq; Steven J Potts, PhD, MBA; Andrew Spiegel, Esq Introduction: In the… Read More »

Non-medical switching of biologicals/biosimilars: Canada, Europe and the US – a webinar report

Published in: Volume 12 / Year 2023 / Issue 1
Page: 23-36

Author byline as per print journal: Michael S Reilly, Esq; Gail Attara; Ralph D McKibbin, MD, FACP, FACG, AGAF; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP Introduction: Biosimilars are… Read More »

Key factors for successful uptake of biosimilars: Europe and the US

Published in: Volume 11 / Year 2022 / Issue 3
Author(s): ,
Page: 112-24

Introduction: Biosimilars were first introduced in Europe in 2006 and then in the US in 2015. An online webinar on the successful uptake in Europe and the US was held… Read More »

3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report

Published in: Volume 9 / Year 2020 / Issue 3
Author(s): , , , ,
Page: 132-44

Author byline as per print journal: Professor John-Joseph Borg, PhD; Yolanda Elias Gramajo, MD; Professor Andrea Laslop, MD; Robin Thorpe, PhD, FRCPath; Jian Wang, MD, PhD Introduction: Biosimilars have the… Read More »

1st ASEAN overview workshop on GMP for biologicals/biosimilars 2018 – Report

Published in: Volume 8 / Year 2019 / Issue 3
Author(s): ,
Page: 119-27

Introduction: The Association of Southeast Asian Nations (ASEAN) Overview Workshop on GMP for Biologicals and Biosimilars was co-organized with the Generics and Biosimilars Initiative (GaBI). This meeting was intended to… Read More »

2nd MENA Stakeholder Meeting on Biosimilars 2018 – Report

Published in: Volume 8 / Year 2019 / Issue 2
Author(s): , ,
Page: 76-87

Introduction: The number of biosimilars, or similar biotherapeutic products, is expanding rapidly worldwide. A further 12 blockbuster biologicals are set to add to this number by 2020. Agreement about the… Read More »

First GCC stakeholder meeting on approval process, interchangeability/substitution and safety of biosimilars 2017 – Report

Published in: Volume 7 / Year 2018 / Issue 4
Author(s): , , , , , , ,
Page: 158-63

Author byline as per print journal: Gianluca Trifirò, MD, PhD; Meteb Al-Foheidi, MD, FRCPC; Ali M Alhomaidan, PhD; Ahmed H Aljedai, PharmD, MBA, BCPS, FCCP, FAST; Musaed Abdullah Alkholief, PhD;… Read More »

First ASEAN educational workshop on regulation and approval of biosimilars/similar biotherapeutic products 2017 – Report

Published in: Volume 7 / Year 2018 / Issue 3
Author(s): , ,
Page: 127-32

Author byline as per print journal: Robin Thorpe, PhD, FRCPath; Elwyn Griffiths, PhD, DSc; Niklas Ekman, PhD Abstract: Biosimilar medicines are being increasingly developed and used worldwide. Many regulatory agencies across… Read More »

Quality assessment of biosimilars in Colombia – reducing knowledge gaps

Published in: Volume 7 / Year 2018 / Issue 2
Author(s): , ,
Page: 79-83

Abstract: Biosimilar medicines are having a global effect, and as such regulatory agencies worldwide are assessing how to respond to them. Here, two events held by GaBI for the Colombian… Read More »

Perspectives on the future of pegfilgrastim biosimilars

Published in: Volume 6 / Year 2017 / Issue 4
Author(s): , ,
Page: 185-7

Author byline as per print journal: Professor Pere Gascón, MD; Ruediger Jankowsky, PhD; Karsten Roth, PhD Abstract: Cinfa Biotech, the biosimilars specialists of the Cinfa Group, reviewed pegfilgrastim biosimilar approaches to… Read More »

Page 1 of 3 1 2 3 Next »
Go Back Print